Bradykinin stimulates tissue plasminogen activator release in human vasculature

Hypertension

Volumn 33, Issue 6, 1999, Pages 1431-1435

  Brown, Nancy J ^a,c   Gainer, James V ^a   Stein, C Michael ^a   Vaughan, Douglas E ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Bradykinin; Endothelium; Plasminogen; Tissue activator

Indexed keywords

ACETYLCHOLINE; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARM BLOOD FLOW; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME RELEASE; FEMALE; FIBRINOLYSIS; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SODIUM DEPLETION; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0033048762     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.33.6.1431     Document Type: Article

References (40)

1. Linz W, Wiemer G, Scholkens BA. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardiol. 1997;80: 118A-123A.
2. Vanhoutte PM. Endothelium and control of vascular function: state of the art lecture. Hypertension. 1989;13:658-667.
3. Hasan AA, Amenta S, Schmaier AH. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation. 1996;94:517-528.
4. Emeis JJ, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions. 1992;38:285-291.
5. Markwardt F, Klocking HP. Studies on the release of plasminogen activator. Thromb Res. 1976;8:217-223.
6. Emeis JJ. Perfused rat hind legs: a model to study plasminogen activator release. Thromb Res. 1983;30:195-203.
7. Brown NJ, Nadeau J, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost. 1997;77:522-525.
8. Chandler WL, Veith RC, Fellingham GW, Levy WC, Schwartz RS, Cerqueira MD, Kahn SE, Larson VG, Cain KC. Beard JC. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Am Coll Cardiol. 1992;19:1412-1420.
9. De Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, Breimer DD, Soons PA, Emeis JJ, Cohen AF. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost. 1992;67:83-87.
10. Jern S, Selin L, Bergbrant A, Jern C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemost. 1994;72:588-594.
11. Wall U, Jern S, Tengborn L, Jern C. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood. 1998;91:529-537.
12. Stein CM, Brown NJ, Vaughan DE, Lang CC, Wood AJJ. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. J Am Coll Cardiol. 1998;32:117-122.
13. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288: 373-376.
14. Bohme E, Graf H, Schultz G. Effects of sodium nitroprusside and other smooth muscle relaxants on cyclic GMP formation in smooth muscle and platelets. Adv Cyclic Nucleotide Res. 1978;9:131-143.
15. Hokanson DE, Sumner DS, Strandness DEJ. An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng. 1975;22:25-29.
16. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis: a prospective study of endogenous tissue plasminogen activator and plasminogen activator inhibitor. Circulation. 1992;85:1822-1827.
17. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1994;653:131-138.
18. Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W. Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol. 1997;139:245-256.
19. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood. 1985;66:835-839.
20. Kawai Y, Matsumoto Y, Watanabe K, Yamamoto H, Satoh K, Murata M, Handa M, Ikeda Y. Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells. Blood. 1996;87:2314-2321.
21. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242-1248.
22. Pedrinelli R, Dell'Omo G, Ferrini L, Morale M, De Negri F, Melillo E, Carmassi F. Acetylcholine-mediated vasodilation and tissue-type plasminogen activator release in normal and hypertensive men. Angiology. 1999;In press.
23. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation. 1995;91:1732-1738.
24. Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther. 1997;62:436-443.
25. Bruning TA, Chang PC, Kemme MJ, Vermeij P, Pfaffendorf M, van Zwieten PA. Comparison of cholinergic vasodilator responses to acetylcholine and methacholine in the human forearm. Blood Press. 1996;5:333-341.
26. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993;88:2149-2155.
27. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.
28. Pinto S, Virdis A, Ghiadoni L, Bernini G, Lombardo M, Petraglia F, Genazzini AR, Taddei S, Salvetti A. Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. Hypertension. 1997;29:268-273.
29. Ueda S, Petrie JR, Cleland SJ, Elliott HL, Connell JM. The vasodilating effect of insulin is dependent on local glucose uptake: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 1998;83:2126-2131.
30. Jern S, Wall U, Bergbrant A, Selin-Sjogren L, Jern C. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension. Arterioscler Thromb Vase Biol. 1997;17:3376-3383.
31. 2-receptor antagonist. Br J Clin Pharmacol. 1994;38:317-321.
32. Vallance P, Collier J, Moncada S. Nitric oxide synthesized from L-arginine mediates endothelium dependent dilation in human veins in vitro. Cardiovasc Res. 23:1053-1057.
33. Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of ACE inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther. 1996;279:703-712.
34. Bonner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol. 1990;15:S46-S56.
35. Newby DE, Wright RA, Dawson P, Ludlam CA, Boon NA, Fox KA, Webb DJ. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovas Res. 1998;38:485-492.
36. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993;22: 579-584.
37. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:1115-1118.
38. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin receptor blockade on response to angiotensin converting enzyme inhibition in salt-deplete normotensive and hypertensive subjects. N Engl J Med. 1998;339:1285-1292.
39. Hornig B, Arakawa N, Smolarski R, Schieffer B, Drexler H. Concomitant enhancement of NO-mediated vasodilation and pro-fibrinolytic activity by ACE inhibition in patients with coronary artery disease. Circulation. 1997;96(suppl I):I-114. Abstract.
40. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1 in humans. Hypertension. 1998;32:965-971.